Pharma Focus Asia

Upperton Pharma Solutions Invests US$6.3 million (£5million) to Expand Sterile Manufacturing Facility in UK

Introduction:

Upperton Pharma Solutions invests US$6.3 million (£5million) to expand its sterile drug manufacturing capacity.

Features:

The newly designed sterile facility will incorporate advanced VHP isolation technology to facilitate GMP fill-finish operations for sterile drug products, encompassing both biologics and small molecules. This expansion aligns with the existing comprehensive services, including full-service formulation development and quality control labs. 

This expansion includes a new 7,000 sqft sterile manufacturing facility. The investment in sterile drug product manufacturing complements the current service portfolio, offering formulation development for various dosage forms, clinical trial supply, and niche-scale commercial manufacture for non-sterile products.

The facility is dedicated to producing aseptic and terminally sterilised small-volume liquids intended for parenteral, ocular, and pulmonary delivery.

This investment addresses a significant industry gap by providing small batches of sterile drug products crucial for early clinical trials.

Construction of the facility is set to commence in February 2024, and the commissioning and validation are targeted for early Q4/2024 completion.

Specifications:

Name      Upperton Pharma Solutions
Type        Expansion
Budget   US$6.3 million (£5million)
Year       2024
 

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference